Cyclo Therapeutics (Cyclo Therapeutics) 5-Year ROIIC % : -466.89% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Cyclo Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was -466.89%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Cyclo Therapeutics's 5-Year ROIIC % or its related term are showing as below:

CYTH's 5-Year ROIIC % is ranked worse than
97.8% of 998 companies
in the Drug Manufacturers industry
Industry Median: 3.765 vs CYTH: -466.89

Cyclo Therapeutics 5-Year ROIIC % Historical Data

The historical data trend for Cyclo Therapeutics's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclo Therapeutics 5-Year ROIIC % Chart

Cyclo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

5-Year ROIIC %

Get a 7-Day Free Trial

238.86

245.18

3,331.10

-1,536.68

-466.89

Cyclo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
5-Year ROIIC %	Get a 7-Day Free Trial															-1,536.68	-	-	-	-466.89

Competitive Comparison of Cyclo Therapeutics's 5-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclo Therapeutics's 5-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Cyclo Therapeutics's 5-Year ROIIC % falls into.

Cyclo Therapeutics 5-Year ROIIC % Calculation

Cyclo Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %	=	5-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	5-Year Incremental Invested Capital^**
	=	( -20.05 (Dec. 2023) - -4.255 (Dec. 2018) )	/	( 3.531 (Dec. 2023) - 0.148 (Dec. 2018) )
	=	-15.795	/	3.383
	=	-466.89%^***

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Cyclo Therapeutics (NAS:CYTH) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Cyclo Therapeutics 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclo Therapeutics (Cyclo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTH) » Definitions » 5-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653

Website

https://www.cyclodex.com

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.

Executives

Vivien Wong	director	6C CHATEAUX CIRCLE, SCARSDALE NY 10583
Rafael Holdings, Inc.	10 percent owner	520 BROAD STREET, NEWARK NJ 07120
William Conkling	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Jeffrey Tate	director, officer: Chief Executive Officer	C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643
Francis Patrick Ostronic	director	932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850
Markus Sieger	director	BEUTSTWEG 12, CH-8032, ZURICH V8 000000000
N Scott Fine	director	600 3RD AVE, NEW YORK NY 10016
Sharon Hemond Hrynkow	officer: SVP for Medical Affairs	4816 KING SOLOMON DRIVE, ANNADALE VA 22003
Lise Lund Kjems	officer: Chief Medical Officer	91 ROLLINGWOOD LN., CONCORD MA 01742
Joshua M Fine	officer: Chief Financial Officer	21 HEMMELSKAMP ROAD, WILTON CT 06897
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Michael Eric Lisjak	officer: Chief Regulatory Officer	12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
L.p. Novit,	10 percent owner	966 HUNGERFORD DRIVE, ROCKVILLE MD 20850